Scientific Advisory Services

Simplify Your Drug Development Challenges

Our Scientific Advisory Services makes it easy. The mix of expertise and experience within our Scientific Advisory Services (SAS) team supports your programs by reducing risk and accelerating timelines to the clinic. SAS ensures that data is relevant and applicable for your end goal, utilizing a comprehensive portfolio for end-to-end drug discovery, and so much more. The team provides flexible, responsive, and personalized support, so you can trust that your project is managed with dedication and personalized attention.

With access to the industry’s most comprehensive portfolio – from early discovery to market support – our team is uniquely qualified to map your journey through drug development.

WEBINAR: Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening
This webinar showcases how the Retrogenix^® platform empowers smarter, earlier decisions across biologic formats. You’ll also learn how this platform, recently accepted into the FDA’s ISTAND Pilot Program, aligns with evolving regulatory support for NAMs and the shift toward reduced animal use.
Watch the Replay

We Can Get You Where You Need to Go with Speed and Precision

Reduce Risk and Accelerate Timelines to the Clinic
Biotechnology developers need a collaborative approach and deep scientific and regulatory support for all modality types (e.g., small molecules, mAbs, oligonucleotides, cell therapy, gene therapy, peptides, etc.) and SAS will provide the best strategy for bringing a novel therapy to market while minimizing risk.

Extend Your Capabilities with Scientific Support
Feel a sense of trust as you collaborate with SAS to fill the gaps and extend the capabilities of your in-house team.

Ensure That the Data Is Relevant and Applicable for Your End Goal
Collaboratively design the most appropriate and cost-efficient studies and customized programs to support your intended clinical trial protocol or product registration.

Navigate the Complex Regulatory Environment
Long-term working relationships with global regulatory bodies inform our delivery of strategic advice on executing an optimal preclinical program. Understanding how and when to plan a preclinical investigational new drug IND-enabling program is an integral part of meeting specific milestones necessary for timely and efficient IND submission.

Utilize a Comprehensive Portfolio for End-to-end Drug Discovery
With numerous technologies for target and hit identification combined with a knowledge-based approach to advance therapies to lead optimization studies in cell systems and animal models, the SAS team consistently delivers successful preclinical candidates.

Dispelling the “Cookie Cutter” Fallacy of Small Molecule IND
View this webinar to discover how to adapt your approach to your IND program’s unique challenges to gain a competitive edge.
Watch the Webinar

Collective Scientific Advisory Services Expertise

Our scientific advisors have over 200 years of collective experience in the pharmaceutical industry, not including postdoctoral experience, equating to 16 years on average for each team member. We have worked with all types of therapies, including: 

• Small molecules, including cytotoxics
• Proteins/Peptides: Enzymes, clotting factors, cytokines, hormones, vaccines
• Antibodies/Antibody-like: mAbs, Fab, scFv, bi-specific, ADC, fusion proteins
• Nucleic acid-based therapeutics: Antisense oligonucleotides (ASO), siRNA, microRNA, mRNA
• Gene therapy: Viral vectors, non-viral delivery
• Cell therapy: Autologous, allogenic, xenogeneic, CAR-T
• Engineered bacteria
• Viruses: Oncolytic, vaccine
• Novel excipients: Nanoparticles, specialty delivery, implants

Start Your Journey